Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 865 2352511, +7 865 2353229.


Matrix metalloproteinases: role in cardiac remodeling in patients with connective tissue dysplasia

[Internal diseases]
Madina Djazaeva; Natalia Gladkikh; Vladimir Reshetnikov; Alexandr Yagoda;

57 men and 43 women, aged 22.0±4.2 years were examined to determine the clinical and prognostic value of matrix metalloproteinases in heart remodeling in CTD. Serum concentrations of MMP-1, MMP-9, TIMP-1 were determined by ELISA («Cloud-Clone Corp.», China). Imbalance of MMP-1, MMP-9 and their inhibitor – TIMP-1 was revealed in patients with CTD. Significant increase in MMP-1 level was registered in cases of MVP with myxomatous degeneration and mitral regurgitation of II degree. Risk of cardiac remodeling progression at three-year follow-up increases in cases of elevated of MMP-1/ TIMP-1 coefficient. Identified changes in the MMPs system in patients with CTD may be used as additional criteria of severity and determination of probability of progression of heart connective tissue structures remodeling.


1. Clinical recommendations of Russian scientific medical society of therapists on diagnosis, treatment and rehabilitation of patients with connective tissue dysplasia (first revision). Meditsinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus. 2018;13(1.2):137-209. (in Russ.). https://doi.org/10.14300/mnnc.2018.13037
2. Nechaeva G. I., Martynov A. I. Displaziya soedinitel’noj tkani: serdechno-sosudistye izmeneniya, sovremennye podhody k diagnostike i lecheniyu. Moskwa : OOO «Medicinskoe informacionnoe agentstvo». 2017. (In Russ.).
3. Kuzmina O. K., Rutkovskaya N. V. Myocardial remodeling in patients with heart valves disorders. Sibirskoe medicinskoe obozrenie. – Siberian Medical Review. 2017;2:5-14. (in Russ.). https://doi.org/10.20333/2500136-2017-2-5-14
4. Rippe M., de Backer J., Kutsche K., Mosquera L. M., Schüler H. [et al.]. Mitral valve prolapse syndrome and MASS phenotype: stability of aortic dilatation but progression of mitral valve prolapse. Int. J. Cardiol. Heart Vasc. 2016;10:39-46. https://doi.org/10.1016/j.ijcha.2016.01.002
5. Naji P., Griffin B. P., Asfahan F., Barr T., Rodriguez L. L. [et al.]. Predictors of long-term outcomes in patients with significant myxomatous mitral regurgitation undergoing exercise echocardiography. Circulation. 2014;129(12):1310-1319. https://doi.org/10.1161/CIRCULATIONAHA.113.005287
6. Delling F. N., Rong J., Larson M. G., Lehman B., Fuller D. [et al.]. Evolution of mitral valve prolapse: insights from the Framingham heart study. Circulation. 2016;133:1688-1695. https://doi.org/10.1161/CIRCULATIONAHA.115.020621
7. Zemtsovskiy E. V., Malev E. G. Malye anomalii serdca i displasticheskie fenotipy. Sankt-Peterburg, 2012. (In Russ.).
8. Yagoda A. V., Gladkikh N. N. Relationship of plasma levels of adhesion molecules and geometrical models of left ventricle in patients with mitral valve prolapse. Meditsinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus. 2016;11:315-319. (In Russ.). https://doi.org/10.14300/mnnc.2016.11065
9. Zangelova T. E., Gladkikh N. N., Yagoda A. V. Prognostic value of vascular endothelial growth factor in patients with mitral valve prolapse and connective tissue dysplasia. Meditsinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus. 2017;4:361-365. (In Russ.). https://doi.org/10.14300/mnnc.2017.12101
10. Amar S., Smith L., Fields G. B. Matrix metalloproteinase collagenolysis in health and disease. Biochim. Biophys. Acta. 2017;1874(11):1940-1951. https://doi.org/10.1016/j.bbamcr.2017.04.015
11. Cieplak P., Strongin A. Y. Matrix metalloproteinases – from the cleavage data to the prediction tools and beyond. Biochim. Biophys. Acta. 2017;1874(11):1952-1963. https://doi.org/10.1016/j.bbamcr.2017.03.010
12. Goncharova N. S., Moiseeva O. M., Shlyakhlo E. V., Aleshina G. M. Matrix metalloproteinases: significance in remodeling of the myocardium in valvular heart disease. Кardiologia. 2007;47(12):49-53.
13. Guy T. S., Hill A. C. Mitral valve prolapse. Ann. Rev. Med. 2012;63;277-292. https://doi.org/10.1146/annurev-med-022811-091602
14. Osipova O. A., Plaxina K. G., Komisov A. A., Godlevskaya O. А. The pathogenetic mechanisms of participation of myocardial extracellular matrix remodeling of the heart in patients with chronic heart failure. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya Medicina. Farmaciya. – Belgorod State University Scientific bulletin. Medicine. Pharmacy. 2015;22:18-25. (In Russ.).
15. Liu J., Khalil R. A. Matrix metalloproteinase inhibitors as investigational and therapeutic tools in unrestrained tissue remodeling and pathological disorders. Prog. Mol. Biol. Tansl. Sci. 2017;148:355-420. https://doi.org/10.1016/bs.pmbts.2017.04.003
16. Yinginer O., Keser N., Ozmen N., Tokatli A., Kardesoglu E., Isilak Z., Uz O., Uzun M. Classic mitral valve prolapse causes enlargement in left ventricle even in the absence of significant mitral regurgitation. Echocardiography. 2012;29:123-129. https://doi.org/10.1111/j.1540-8175.2011.01544.x

Keywords: matrix metalloproteinases, connective tissue dysplasia, cardiac remodeling

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy